

APUA

ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS

Chief Executive Officers

Stuart B. Levy, President
Thomas F. O'Brien, Vice President
Kathleen T. Young, Exec. Director

Board of Directors

Stuart B. Levy, Chairman
Harris A. Berman
Barbara Shattuck Dubow
Ellen L. Koenig
Morton A. Madoff
Bonnie Marshall
Thomas F. O'Brien
Arnold G. Reinhold
Philip D. Walson
Fred B. Wilcon

Scientific Advisory Board

Jacques F. Acar, France
Werner Arber, Switzerland
Fernando Baquero, Spain
Michael L. Bennish, USA
Jose Ramiro Cruz, Guatemala
Iwan Darmansjah, Indonesia
Julian Davies, Canada
Stanley Falkow, USA
Walter Gilbert, USA
Herman Goossens, Belgium
Sherwood L. Gorbach, USA
Ian M. Gould, Scotland
George Jacoby, USA
Janusz Jeljaszewicz, Poland
Calvin M. Kunin, USA
Yankel Kupersztuch, USA
Joshua Lederberg, USA
Stephen A. Lerner, USA
Donald E. Low, Canada
Leonardo Mata, Costa Rica
Richard P. Novick, USA
Jorge Olarte, Mexico
Maria Eugenia Pinto, Chile
Vidal Rodriguez-Lemoine,
Venezuela
Theodore Sacks, Israel
José Ignacio Santos, Mexico
Mervyn Shapiro, Israel
K. B. Sharma, India
Atef M. Shibl, Saudi Arabia
Ewe Hui Sng, Singapore
Tze-ying Tai, China
Thelma E. Tupasi, Philippines
Anne K. Vidaver, USA
Frantisek Vymola, Czech Republic
Fu Wang, China
Bernd Wiedemann, Germany

Headquarters

APUA
75 Kneeland St.
Boston, MA 02111, USA

Telephone: 617-636-0966

Fax: 617-636-3999

Email: apua@opal.tufts.edu

Website: www.APUA.org

November 27, 2000

Ref: CVM doc. # 00N - 1571


Helge H. Wehmeier
President and Chief Executive Officer
Bayer Corporation
100 Bayer Road
Pittsburgh, PA 15205-9741

Dear Mr. Wehmeier,


This letter is to notify the US Food and Drug Administration and the Bayer Corporation of the Alliance for the Prudent Use of Antibiotics' (APUA's) support of the FDA proposal to withdraw the fluoroquinolone antibiotic enrofloxacin (trade name Baytril®) from use in poultry in the United States. APUA has previously registered concern that use of fluoroquinolones in food animals can result in the emergence of resistant strains of bacteria that will travel to people through food.

Now there is enough evidence to provide a link between the introduction of fluoroquinolones for use in food animals and the development of resistant strains in *Campylobacter* and *Salmonella*. We therefore encourage strong regulatory action on the part of the FDA and voluntary compliance on the part of Bayer. We are concerned that any delay in the withdrawal of this antibiotic will result in higher levels of resistance and consequently additional public health risks. Thank you for your consideration.

Sincerely,



Stuart B. Levy, MD
President, APUA



Kathleen T. Young
Executive Director, APUA

cc: FDA